You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Bulk Pharmaceutical API Sources for METHYLDOPA AND HYDROCHLOROTHIAZIDE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for METHYLDOPA AND HYDROCHLOROTHIAZIDE

Vendor Vendor Homepage Vendor Sku API Url
Starshine Chemical ⤷  Get Started Free 2023-05-5H02570 ⤷  Get Started Free
RR Scientific ⤷  Get Started Free R6386117 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: METHYLDOPA AND HYDROCHLOROTHIAZIDE

Last updated: July 30, 2025


Introduction

The procurement of bulk Active Pharmaceutical Ingredients (APIs) is a critical aspect of pharmaceutical manufacturing, impacting both quality assurance and supply chain reliability. MethylDOPA and Hydrochlorothiazide are established antihypertensive agents, widely prescribed worldwide. Identifying trusted API sources for these compounds ensures regulatory compliance and manufacturing consistency. This analysis highlights leading global API manufacturers, quality considerations, and strategic sourcing insights for these drugs.


Market Overview of MethylDOPA and Hydrochlorothiazide APIs

MethylDOPA (α-methyldopa) and Hydrochlorothiazide (HCTZ) are essential medicines, often used in combination therapy for hypertension. Their APIs are produced primarily in regions with established pharmaceutical manufacturing capabilities, including India, China, Europe, and the United States.

MethylDOPA API is less commonly produced than newer antihypertensives but retains importance in specific clinical scenarios, especially in pregnancy-indicated hypertension. Hydrochlorothiazide API remains one of the most prescribed diuretics globally, with high-volume manufacturing.


Global API Manufacturing Landscape

Key Regions and Leading API Producers

India

India remains a dominant API manufacturing hub, accounting for a significant share of global supply, especially for generics. Established companies such as Sun Pharma, Dr. Reddy’s Laboratories, and Aurobindo Pharma produce high-quality MethylDOPA and Hydrochlorothiazide APIs, often compliant with international standards (e.g., USFDA, EMA).

China

Chinese API manufacturers offer competitive pricing and extensive manufacturing capabilities. Companies like Zhejiang Hisoar Pharmaceutical and Zhejiang Huahai Pharmaceutical provide bulk APIs for both MethylDOPA and Hydrochlorothiazide, emphasizing quality controls aligned with international regulatory norms.

Europe and the United States

While production volumes are lower compared to India and China, some European and US-based manufacturers focus on high-purity, high-specification APIs. These companies often serve niche markets and in some cases, fulfill specialized regulatory or quality requirements.


Prominent API Suppliers for MethylDOPA

Indian Manufacturers

  • Aurobindo Pharma: Known for its compliance with cGMP standards, Aurobindo offers MethylDOPA API meeting USP/NF specifications.
  • Sun Pharma: Provides bulk MethylDOPA API with consistent quality, serving global markets.
  • Strides Pharma: Offers high-purity MethylDOPA API suitable for regulated markets.

Chinese Manufacturers

  • Zhejiang Hisoar Pharmaceutical: Produces MethylDOPA with quality certifications aligned to international standards.
  • Zhejiang Huahai Pharmaceutical: Offers cost-effective API options with extensive regulatory compliance.

Certifications & Quality Standards

Leading suppliers typically hold certifications such as USFDA, EMA, ISO 9001, and GMP compliance. These ensure APIs meet pharmaceutical quality requirements, reducing downstream regulatory risks.


Prominent API Suppliers for Hydrochlorothiazide

Indian Manufacturers

  • Dr. Reddy’s Laboratories: Supplies Hydrochlorothiazide API with comprehensive documentation and regulatory approvals.
  • Aurobindo Pharma: Offers high-purity HCTZ API, adhering to pharmacopoeial standards.
  • Cipla: Provides cost-effective API options with proven compliance histories.

Chinese Manufacturers

  • Zhejiang Ausu Pharmaceutical: Responsible for large-scale Hydrochlorothiazide API production, certified for global export.
  • Hubei Bosheng: Supplies API with sufficient regulatory documentation and manufacturing capacity.

Certifications & Quality

These suppliers comply with rigorous Good Manufacturing Practice (GMP) standards, ensuring batch-to-batch consistency and regulatory compliance (e.g., DMF filings, CE Mark, etc.).


Supply Chain and Sourcing Strategies

Considerations for Buyers

  • Regulatory Compliance: Verify supplier certifications, including USFDA DMF, EMA certification, and ISO standards.
  • Quality Assurance: Ensure analytical validation, stability data, and batch records are available and meet pharmacopoeial standards.
  • Pricing & Capacity: Balance cost-effectiveness with manufacturing capacity and lead time.
  • Geopolitical Stability: Mitigate risks associated with supply disruptions due to regional instability or trade restrictions.

Emerging Trends

  • Quality by Design (QbD): Increasing adoption among suppliers enhances API quality.
  • Vertical Integration: Some pharmaceutical companies integrate API manufacturing to secure supply chains.
  • Regulatory Harmonization: Uniform standards facilitate easier approval processes across markets.

Regulatory and Quality Considerations

Regulatory authorities scrutinize API sources, emphasizing Good Manufacturing Practices (GMP), thorough documentation, and compliance with Pharmacopoeias (USP, EP, BP). Suppliers with established regulatory filings (DMF, CEP, ANDA) tend to be preferred, reducing approval timelines.


Conclusion

Securing reliable API sources for MethylDOPA and Hydrochlorothiazide demands due diligence in evaluating quality, compliance, and supply stability. India and China dominate the manufacturing landscape, with numerous certified suppliers capable of meeting global standards. Strategic partnerships with accredited manufacturers facilitate compliance, cost management, and uninterrupted supply for pharmaceutical formulations.


Key Takeaways

  • Indian and Chinese manufacturers lead API supply for MethylDOPA and Hydrochlorothiazide, offering cost-effective and high-quality options.
  • Verification of certifications such as USFDA, EMA, and GMP compliance is essential to mitigate regulatory risk.
  • Long-term supply agreements with proven suppliers enable stability amid global market fluctuations.
  • Incorporating quality assurance measures early can streamline regulatory approval processes.
  • Monitoring geopolitical and trade developments is critical to maintain resilient supply chains.

FAQs

1. What are the most reputable API manufacturers for MethylDOPA?
Leading global suppliers include Aurobindo Pharma, Sun Pharma, and Zhejiang Hisoar Pharmaceutical, all recognized for GMP compliance and regulatory certifications.

2. How can I verify the quality of Hydrochlorothiazide APIs?
Ensure suppliers have valid DMFs, GMP certifications, and compliance with pharmacopoeial standards. Request analytical validation data, stability reports, and regulatory documentation.

3. Are Chinese API manufacturers a reliable source for these compounds?
Yes, many Chinese firms maintain high regulatory and quality standards, especially those with certifications such as GMP, USFDA, or ISO. Due diligence is advised.

4. What are key regulatory considerations when sourcing APIs?
Confirm supplier compliance with international standards, verify certification documentation, and ensure APIs meet pharmacopoeial specifications specified in the product dossier.

5. How do geopolitical factors influence API sourcing?
Trade restrictions, tariffs, or regional instability can impact supply continuity. Diversifying API sources and establishing backup suppliers mitigate these risks.


References

  1. [1] U.S. Food and Drug Administration (FDA). Drug Master Files (DMFs).
  2. [2] European Medicines Agency (EMA). API Quality Standards.
  3. [3] IQVIA. Global API Manufacturing Capacity and Trends, 2022.
  4. [4] Pharmaceutical Technology. "The Rising Role of Indian API Manufacturers," 2021.
  5. [5] China Pharmaceutical Guide. "Top API Producers," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.